Suchergebnisse - "Carcinoma, Squamous Cell genetics"

  1. 1

    Quelle: Oncoimmunology
    OncoImmunology, Vol 14, Iss 1 (2025)
    Oncoimmunology, vol. 14, no. 1, pp. 2457797

    Dateibeschreibung: application/pdf

  2. 2

    Quelle: Head Face Med
    Head & Face Medicine, Vol 20, Iss 1, Pp 1-9 (2024)

    Dateibeschreibung: application/pdf

  3. 3
  4. 4
  5. 5

    Weitere Verfasser: Broghammer, Felix Korovina, Irina Gouda, Mahesh et al.

    Quelle: Mol Cancer
    Molecular Cancer, Vol 23, Iss 1, Pp 1-25 (2024)

    Schlagwörter: 0301 basic medicine, Cancer Research, Squamous Cell/drug therapy, Integrin beta1/genetics, Radioprotection, Epithelial-Mesenchymal Transition, Adaptive resistance, Antineoplastic Agents, HNSCC, Cell Line, Tumor [MeSH], Epidermal growth factor receptor, Humans [MeSH], β1 integrin, Head and Neck Neoplasms/genetics [MeSH], Squamous Cell Carcinoma of Head and Neck/drug therapy [MeSH], Head and Neck Neoplasms/drug therapy [MeSH], Carcinoma, Squamous Cell/drug therapy [MeSH], Squamous Cell Carcinoma of Head and Neck/genetics [MeSH], Radiosensitization, Epithelial-Mesenchymal Transition/genetics [MeSH], ErbB Receptors/metabolism [MeSH], Epithelial-to-mesenchymal transition, Receptor Protein-Tyrosine Kinases/genetics [MeSH], Integrin beta1/genetics [MeSH], Research, Antineoplastic Agents/therapeutic use [MeSH], Carcinoma, Squamous Cell/genetics [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Phenotype [MeSH], Fibroblast growth factor receptor, Cell Line, 03 medical and health sciences, Epithelial-Mesenchymal Transition/genetics, Cell Line, Tumor, Squamous Cell Carcinoma of Head and Neck/drug therapy, Humans, RC254-282, ErbB Receptors/metabolism, 0303 health sciences, Tumor, Squamous Cell Carcinoma of Head and Neck, Receptor Protein-Tyrosine Kinases/genetics, Integrin beta1, Carcinoma, Antineoplastic Agents/therapeutic use, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Receptor Protein-Tyrosine Kinases, Head and Neck Neoplasms/drug therapy, 3. Good health, ErbB Receptors, Phenotype, Oncology, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Molecular Medicine

    Dateibeschreibung: application/pdf

  6. 6

    Quelle: Oncogene
    Oncogene : including Oncogene reviews 39(44), 6856-6870 (2020). doi:10.1038/s41388-020-01465-y

    Schlagwörter: Male, Carcinoma, Transitional Cell, Receptor, ErbB-3, Receptor, ErbB-2, Drug Synergism, Gefitinib, Article, 3. Good health, Bladder cancer, Gene Expression Regulation, Neoplastic [MeSH], Urinary Bladder/pathology [MeSH], Cell Line, Tumor [MeSH], Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Drug Synergism [MeSH], Urinary Bladder Neoplasms/drug therapy [MeSH], Cohort Studies [MeSH], Carcinoma, Transitional Cell/pathology [MeSH], ErbB Receptors/metabolism [MeSH], Carcinoma, Transitional Cell/genetics [MeSH], Male [MeSH], Carcinoma, Transitional Cell/drug therapy [MeSH], Receptor, ErbB-2/antagonists, Gefitinib/therapeutic use [MeSH], Signal Transduction/drug effects [MeSH], Urinary Bladder Neoplasms/genetics [MeSH], Receptor, ErbB-4/metabolism [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Female [MeSH], Drug Resistance, Neoplasm/drug effects [MeSH], Protein Kinase Inhibitors/pharmacology [MeSH], ErbB Receptors/antagonists, Humans [MeSH], Gene Knockdown Techniques [MeSH], ErbB Receptors/genetics [MeSH], Erlotinib Hydrochloride/therapeutic use [MeSH], Receptor, ErbB-3/metabolism [MeSH], Urinary Bladder Neoplasms/pathology [MeSH], Protein Kinase Inhibitors/therapeutic use [MeSH], Carcinoma, Squamous Cell/drug therapy [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Gefitinib/pharmacology [MeSH], Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH], Receptor, ErbB-4/antagonists, Growth factor signalling, Carcinoma, Squamous Cell/genetics [MeSH], Receptor, ErbB-3/antagonists, RNA, Small Interfering/metabolism [MeSH], Erlotinib Hydrochloride/pharmacology [MeSH], Cohort Studies, ErbB Receptors, Gene Expression Regulation, Neoplastic, Erlotinib Hydrochloride, 03 medical and health sciences, 0302 clinical medicine, Drug Resistance, Neoplasm, Cell Line, Tumor, Gene Knockdown Techniques, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Humans, Female, RNA, Small Interfering, Protein Kinase Inhibitors, Aged

  7. 7

    Quelle: Cancer letters, vol. 484, pp. 50-64

    Dateibeschreibung: application/pdf

  8. 8

    Quelle: Oncogene

    Schlagwörter: 0301 basic medicine, 0303 health sciences, Oncogene Proteins, Fusion, Sialoglycoproteins, Tumor Suppressor Proteins, Medizin, Nuclear Proteins, Antineoplastic Agents, Brief Communication, Heterocyclic Compounds, 4 or More Rings, Peptide Fragments, 3. Good health, Proto-Oncogene Proteins c-myc, 03 medical and health sciences, Drug Delivery Systems, Protein Domains, Cell Line, Tumor, Carcinoma, Squamous Cell, Humans, Proto-Oncogene Proteins c-myc/metabolism [MeSH], Target identification, Cell Line, Tumor [MeSH], Tumor Suppressor Proteins/genetics [MeSH], Peptide Fragments/metabolism [MeSH], Transcription Factors/genetics [MeSH], Heterocyclic Compounds, 4 or More Rings/pharmacology [MeSH], Sialoglycoproteins/metabolism [MeSH], Protein Domains [MeSH], Antineoplastic Agents/pharmacology [MeSH], Peptide Fragments/antagonists, Tumor Suppressor Proteins/metabolism [MeSH], Nuclear Proteins/metabolism [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Targeted therapies, Transcription Factors/metabolism [MeSH], Antineoplastic Agents/chemistry [MeSH], Peptide Fragments/genetics [MeSH], Humans [MeSH], Drug Delivery Systems [MeSH], Sialoglycoproteins/genetics [MeSH], Oncogene Proteins, Fusion/genetics [MeSH], Heterocyclic Compounds, 4 or More Rings/chemistry [MeSH], Carcinoma, Squamous Cell/drug therapy [MeSH], Nuclear Proteins/genetics [MeSH], Proto-Oncogene Proteins c-myc/genetics [MeSH], Sialoglycoproteins/antagonists, Carcinoma, Squamous Cell/genetics [MeSH], Oncogene Proteins, Fusion/metabolism [MeSH], Carcinoma, Squamous Cell/metabolism [MeSH], Transcription Factors

  9. 9
  10. 10

    Quelle: Clin Epigenetics

  11. 11

    Quelle: J Otolaryngol Head Neck Surg
    Journal of Otolaryngology-Head and Neck Surgery, Vol 51, Iss 1, Pp 1-9 (2022)
    Journal of Otolaryngology, vol 51, iss 1

    Dateibeschreibung: application/pdf

  12. 12

    Quelle: The Journal of clinical investigation, vol. 128, no. 6, pp. 2581-2599
    Journal of Clinical Investigation

    Dateibeschreibung: application/pdf

  13. 13

    Autoren: Tao Yan Guoyuan Ma Kai Wang et al.

    Quelle: Front Immunol
    Frontiers in Immunology, Vol 12 (2021)
    Frontiers in immunology, 12:547333

  14. 14

    Quelle: Oncotarget
    Oncotarget, vol. 7, no. 37, pp. 58717-58727

    Dateibeschreibung: application/pdf

  15. 15

    Weitere Verfasser: Mamunur Rashid Marc J Williams Inês Sequeira et al.

    Quelle: Nat Commun
    Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
    Sequeira, I, Rashid, M, Tomás, I M, Williams, M J, Graham, T A, Adams, D J, Vigilante, A & Watt, F M 2020, ' Genomic landscape and clonal architecture of mouse oral squamous cell carcinomas dictate tumour ecology ', Nature Communications, vol. 11, no. 1, 5671 . https://doi.org/10.1038/s41467-020-19401-9

    Dateibeschreibung: application/pdf; Electronic

  16. 16

    Quelle: Winther, M, Alsner, J, Tramm, T, Holtved, E, Baeksgaard, L & Nordsmark, M 2016, ' Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer ', Acta Oncologica, vol. 55, no. 5, pp. 652-655 . https://doi.org/10.3109/0284186X.2015.1114680
    Winther, M, Alsner, J, Tramm, T, Holtved, E, Baeksgaard, L & Nordsmark, M 2016, 'Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer', Acta Oncologica, vol. 55, no. 5, pp. 652-5. https://doi.org/10.3109/0284186X.2015.1114680

  17. 17

    Weitere Verfasser: Jun Jing Qiao Fang Fang Li Yan Ru Qin et al.

    Quelle: Cancer Research. 74:840-851

  18. 18

    Autoren: Sun, L Fong, Y Sham, JST et al.

    Quelle: Genes, Chromosomes and Cancer. 30:254-260

    Dateibeschreibung: 1048742 bytes; 257990 bytes; application/pdf

  19. 19
  20. 20

    Weitere Verfasser: Jin Hee Kim Takashi Kohno In-Jae Oh et al.

    Quelle: Nature Genetics. 44:1330-1335